Hélène Negre

Gil Beyen

Filipe Pereira

Etienne Jousseaume

Dora Hammerl

Chris Baldwin

Carole Sansoz

Bernd Eschgfäller

Mateja Kramar

Mateja is associated with technology, innovation, and sustainability, with deep knowledge and experience of regenerative agriculture, responsible sourcing, supply chain optimisation and digital transformation.  In her dual role at Accenture, she combines co-developing technology-driven, innovative, sustainability solutions (Amplify Program) with helping clients solve their biggest and most urgent industrial and global challenges.

Mateja has over 25 years of international experience in many different industries; advising and working on disruptive innovation, reinvention, and optimisation of business models.

Before joining Accenture, Mateja was a Sustainability Advisor at Microsoft. Prior to that, she was leading a variety of start-up and spin-off projects at the ETH Zurich, where she is still working as a guest lecturer on sustainability, technology, and innovation. Mateja is a serial entrepreneur – with over 20 years’ experience, founding 14 successful companies with patent pending innovations, in 8 different industries.

As a former professional athlete and ballet dancer, she is last 15 years working as mentor and coach, focusing on winning performance and personal growth, for both business leaders and professional sports teams. Mateja holds a MSc in Business Administration and Marketing and speaks six languages. She lives in Switzerland, spending most of her free time outdoors with her dog, and practicing several sports.

Her personal quote and motto: Action always beats intention

Benjamin Rengstl

Dr. Benjamin Rengstl is a trained physician and biochemist. Since 2009, he is exploring the potential of the immune system to combat cancer and infectious diseases. Between 2014 and 2016, he received his approbation as well as a PhD and a MD degree from the University of Frankfurt, Germany. During his postdoctoral training, he developed chimeric antigen receptor (CAR)-engineered T-cell therapies against lymphomas and got trained in clinical pathology. In 2017, he joined BioNTech SE located in Mainz to develop a clinical CAR-T cell candidate for treatment of solid tumors. To improve CAR-T cell therapy, his team pioneered an in vivo expansion concept based on a liposomally formulated RNA vaccine for systemic delivery of CAR antigen (CAR T-cell Amplifying RNA Vaccine, CARVac). A FIH clinical trial assessing BioNTech´s novel CLDN6-specific CAR in combination with CARVac is currently ongoing. Furthermore, he is leading multiple programs to develop next generation cell- and RNA-based immunotherapies and further takes technology agnostic approaches to create new strategies for controlled modulation of the immune system.